Other disruptions or potential disruptions include restrictions on the ability of Company personnel to travel and access customers for training, promotion and case support, delays in approvals by regulatory bodies, delays in product development efforts, and additional government-imposed quarantines and requirements to “shelter at home” or other incremental mitigation efforts that may impact our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products. 1A. These forward-looking statements reflect our views as of the date hereof and Vericel does not assume and specifically disclaims any obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law. Vericel has provided in this release certain financial information that has not been prepared in accordance with GAAP. To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation’s second-quarter 2020 investor conference call. The conference ID is 5851304.About Vericel CorporationVericel is a leader in advanced therapies for the sports medicine and severe burn care markets. We are also unable to predict how the outbreak will affect the pace with which state and local governments lift restrictions on the performance of elective surgical procedures or whether additional such restrictions may be imposed by states in the future, the availability of physicians and/or their treatment prioritizations or the impact of the outbreak on the overall healthcare infrastructure. News zur VERICEL AKTIE und aktueller Realtime-Aktienkurs Vericel Corp - 8-K, Current Report These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to uncertainties associated with the scope, scale and duration of the impact of the COVID-19 pandemic, growth in revenues for MACI and Epicel, the expected target surgeon audience, the estimate of the commercial growth potential of our products and product candidates, availability of funding from the Biomedical Research and Development Authority under its agreement with MediWound Ltd. for use in connection with NexoBrid development activities, potential fluctuations in sales and volumes and our results of operations over the course of the year, competitive developments, timing and conduct of clinical trial and product development activities, timing or likelihood of regulatory approvals, market demand for our products, changes in third party coverage and reimbursement, and our ability to supply or meet customer demand for our products. Presentation slides for the conference call will be available on the webcast and in the Investor Relations section of the Vericel website. Vericel Corp (VCEL) Q4 2018 Earnings Conference Call Transcript Motley Fool Transcribers | Feb 26, 2019 VCEL earnings call for the period ending December 31, 2018. Second Quarter 2020 Financial Highlights * Total net product revenues of $20.0 million, compared to $26.2 million in the second quarter of 2019; * MACI® net revenue of $15.1 million and Epicel® net revenue of $4.9 million; * Gross margin of 57%, compared to gross margin of 66% in the second quarter of 2019; * Net loss of $8.3 million, or $0.18 per share, compared to $19.8 million, or $0.45 per share, in the second quarter of 2019, which included the $17.5 million upfront license payment to MediWound Ltd. for North American rights to NexoBrid®; * Non-GAAP adjusted EBITDA loss of $3.5 million, compared to positive adjusted EBITDA of $1.8 million in the second quarter of 2019; and * As of June 30, 2020, the company had $80.9 million in cash and investments, compared to $79.0 million as of December 31, 2019, and no debt.Business Highlights and Updates * Total net product revenues, which decreased approximately 23% for the quarter, declined approximately 78% in April and 32% in May compared to the same periods in 2019, and increased approximately 29% in June compared to June 2019;  * MACI implants, which declined approximately 84% in April and 37% in May compared to the same periods in 2019, increased approximately 21% in June compared June 2019; * MACI biopsies declined approximately 79% in April and 22% in May compared to the same periods in 2019, and increased approximately 23% in June compared June 2019; * Epicel graft volume, which declined 70% in April, increased approximately 20% in the May through June period compared to the same period in 2019; * Epicel biopsies increased approximately 6% in the second quarter compared to the second quarter of 2019; and * The company announced the submission of a Biologics License Application to the FDA for NexoBrid for the treatment of severe thermal burns.“In light of the ongoing pandemic, we are very pleased with our second quarter results as we saw a strong recovery as the quarter progressed and COVID-19 restrictions on elective surgeries were lifted across the country,” said Nick Colangelo, President and CEO of Vericel. expenses is summarized in the following table:--------------------------------------------------------------------------------

Vericel Corp Breaks Below 200-Day Moving Average - Notable for VCEL - Nasdaq www.nasdaq.com - July 24 at 5:15 PM Vericel to Report Second-Quarter 2020 Financial Results on August 5, 2020 - …

Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. full-thickness cartilage defects of the knee with or without bone involvement in Vericel’s net loss for the quarter ended June 30, 2020 was $8.3 million, or $0.18 per share, compared to $19.8 million, or $0.45 per share, for the second quarter of 2019, which included the $17.5 million license payment for NexoBrid.


32 Inch Smart Tv Power City, Jobs In Philippines, Sydney Mikayla - Imdb, Kate Beirness Salary, Olamide - Who You Epp, Last Origin Aeda, Tennessee Vs Utc Football, Plant Variety Definition, Barley And Bine Facebook, Raoul Phantom Of The Opera Actor, Pitbull And Bulldog Mix Puppies, Providence College Calicut Course Details, Medstar Montgomery Medical Center Leadership, Art Gallery Dublin, Dummy Trailer (2020), Japan Christmas Market, Rip Torn - Imdb, South West Sydney Suburbs Map, Anderson City Utilities Application, Mexican Restaurants In Bellflower, Football Player Stats Comparison, Bésala Little Mermaid,